Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients

<div>CEACAM1 protein expression in clinical tumor tissue samples. (a) Representative Western blot results of CEACAM1 expression in ovarian carcinomas (left) and distribution of the relative expression within the cohort (right). Protein extract from the ovarian cancer cell lines OAW42 was included in each gel as an internal control. (b) Kaplan–Meier analysis showing correlations of high CEACAM1 protein expression with longer recurrence-free survival and overall survival. (c, d) Kaplan–Meier analysis and log-rank tests, stratified for tumors with (<svg height="11.5173pt" id="M21" style="vertical-align:-3.129319pt" version="1.1" viewbox="-0.0498162 -8.38798 37.8191 11.5173" width="37.8191pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M169 380V459C122 440 66 423 24 416V392C86 384 90 382 90 317V-135C90 -201 81 -207 17 -213V-240H253V-213C176 -207 169 -201 169 -125V6C182 -1 208 -11 238 -12C368 12 487 109 487 260C487 358 421 449 310 449C298 449 279 444 261 433L169 380ZM169 346C196 367 237 389 269 389C341 389 403 329 403 221C403 109 347 37 263 37C228 37 191 53 169 76V346Z" id="g121-110"></path></g><g transform="matrix(.013,0,0,-0.013,6.812,0)"><path d="M719 650H483V622C553 619 576 606 581 560C585 532 588 487 588 394V148H585L167 650H20V622C67 618 88 610 109 585C127 562 129 557 129 484V264C129 173 126 124 123 93C118 44 92 31 35 28V0H272V28C204 32 181 44 176 95C173 124 170 172 170 264V515H172L598 -9H629V394C629 487 631 532 635 563C639 606 663 619 719 622V650Z" id="g121-76"></path></g><g transform="matrix(.013,0,0,-0.013,20.103,0)"><path d="M535 323V373H52V323H535ZM535 138V188H52V138H535Z" id="g117-34"></path></g><g transform="matrix(.013,0,0,-0.013,31.366,0)"><path d="M384 0V27C293 34 287 42 287 114V635C232 613 172 594 109 583V559L157 557C201 555 205 550 205 499V114C205 42 199 34 109 27V0H384Z" id="g113-50"></path></g></svg>) and without (<svg height="11.5173pt" id="M22" style="vertical-align:-3.129319pt" version="1.1" viewbox="-0.0498162 -8.38798 37.8191 11.5173" width="37.8191pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M169 380V459C122 440 66 423 24 416V392C86 384 90 382 90 317V-135C90 -201 81 -207 17 -213V-240H253V-213C176 -207 169 -201 169 -125V6C182 -1 208 -11 238 -12C368 12 487 109 487 260C487 358 421 449 310 449C298 449 279 444 261 433L169 380ZM169 346C196 367 237 389 269 389C341 389 403 329 403 221C403 109 347 37 263 37C228 37 191 53 169 76V346Z" id="g121-110"></path></g><g transform="matrix(.013,0,0,-0.013,6.812,0)"><path d="M719 650H483V622C553 619 576 606 581 560C585 532 588 487 588 394V148H585L167 650H20V622C67 618 88 610 109 585C127 562 129 557 129 484V264C129 173 126 124 123 93C118 44 92 31 35 28V0H272V28C204 32 181 44 176 95C173 124 170 172 170 264V515H172L598 -9H629V394C629 487 631 532 635 563C639 606 663 619 719 622V650Z" id="g121-76"></path></g><g transform="matrix(.013,0,0,-0.013,20.103,0)"><path d="M535 323V373H52V323H535ZM535 138V188H52V138H535Z" id="g117-34"></path></g><g transform="matrix(.013,0,0,-0.013,31.366,0)"><path d="M241 635C89 635 35 457 35 312C35 153 89 -12 240 -12C390 -12 443 166 443 312C443 466 390 635 241 635ZM238 602C329 602 354 454 354 312C354 172 330 22 240 22C152 22 124 173 124 313S148 602 238 602Z" id="g113-49"></path></g></svg>) nodal involvement. High CEACAM1 expression correlated significantly with shorter recurrence-free survival and overall survival only in patients without nodal involvement.</div>

Disease Markers

fig2

Figure 2

Figure 2: Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients 